Wednesday, November 19, 2014
Print Current Session:
|
|
Wednesday
SESSION 30:
NEW CONCEPTS, DIFFERING VIEWPOINTS, CONTROVERSIES IN VASCULAR DISEASE AND ITS TREATMENT
Moderators:Enrico Ascher, MD / Herbert Dardik, MD
|
|
SESSION 30 SCHEDULE | |
1:00 PM - 1:05 PM | Appropriate Genome-Based Antiplatelet Treatment Should Be A Prerequisite For All Interventional Treatments |
Presenter(s):Karthikeshwar Kasirajan, MD | |
View Abstract | |
1:06 PM - 1:11 PM | Combined Anatomic-Functional Testing With Coronary CT Angiography And Functional Flow Dynamics Is A Game Changer In Evaluating Cardiac Status In Vascular Patients: It Will Replace All Other Diagnostic Tests |
Presenter(s):Christopher K. Zarins, MD | |
View Abstract | |
1:12 PM - 1:17 PM | Value Of Biomarkers For Arteriosclerosis In Predicting Cardiac Risk In Vascular Patients |
Presenter(s):Peter Henke, MD | |
View Abstract | |
1:18 PM - 1:23 PM | Monocyte Phenotyping: A Sensitive Biomarker For Predicting Adverse Vascular Events |
Presenter(s):John P. Fletcher, MD | |
View Abstract | |
1:24 PM - 1:29 PM | Update On The RCT Of Venous Balloon Angioplasty Of Venous Balloon Angioplasty vs. Venography Placebo: What Does It Tell Us |
Presenter(s):L. Nelson Hopkins, MD | |
View Abstract | |
1:30 PM - 1:35 PM | What Is SPY Technology And How Can It Help Vascular Specialists And Vascular Patients |
Presenter(s):Wei Zhou, MD | |
View Abstract | |
1:36 PM - 1:41 PM | DEBATE: Off Label Use Of EVAR Devices Leads To Higher Failure Rates |
Presenter(s):Andres Schanzer, MD | |
View Abstract | |
1:42 PM - 1:47 PM | DEBATE: Not So! Off-Label Use Of Newer EVAR Devices Does Not Lead To Higher Failure Rates: Why The Discrepancy |
Presenter(s):B. Patrice Mwipatayi, FRACS | |
View Abstract | |
1:48 PM - 1:53 PM | Saccular AAAs Behave Differently From Fusiform AAAs Of The Same Diameter: How Should It Influence Our Treatment: Is There Proof |
Presenter(s):Jacques Busquet, MD | |
View Abstract | |
1:54 PM - 1:59 PM | DEBATE: How Far Should We Go With Endovascular Treatment Of Challenging CTOs Causing CLI: An Interventionalist’s Point Of View |
Presenter(s):Craig M. Walker, MD | |
View Abstract | |
2:00 PM - 2:05 PM | DEBATE: How Far Should We Go With Endovascular Treatment Of Challenging CTOs Causing CLI: An Endocompetent Vascular Surgeon’s View |
Presenter(s):Bruce A. Perler, MD, MBA | |
View Abstract | |
2:06 PM - 2:13 PM | Panel Discussion |
END OF SESSION 30 | |
previous | next |